Inhibition of MEK1 Signaling Pathway in the Liver Ameliorates Insulin Resistance
Although mitogen-activated protein kinase kinase (MEK) is a key signaling molecule and a negative regulator of insulin action, it is still uncertain whether MEK can be a therapeutic target for amelioration of insulin resistance (IR) in type 2 diabetes (T2D) in vivo. To clarify whether MEK inhibition...
Saved in:
Main Authors: | Atsunori Ueyama, Nobuhiro Ban, Masanori Fukazawa, Tohru Hirayama, Minako Takeda, Tatsuo Yata, Hiroyasu Muramatsu, Masaki Hoshino, Marii Yamamoto, Masao Matsuo, Yuka Kawashima, Tatsuhiko Iwase, Takehisa Kitazawa, Youichi Kushima, Yuichiro Yamada, Yoshiki Kawabe |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2016-01-01
|
Series: | Journal of Diabetes Research |
Online Access: | http://dx.doi.org/10.1155/2016/8264830 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Targeting KRAS‐mutant pancreatic cancer through simultaneous inhibition of KRAS, MEK, and JAK2
by: Satoru Miyazaki, et al.
Published: (2025-02-01) -
MEK1/2 Inhibitor (GDC0623) Promotes Osteogenic Differentiation of Primary Osteoblasts Inhibited by IL-1β through the MEK-Erk1/2 and Jak/Stat3 Pathways
by: Zeng-Qiao Zhang, et al.
Published: (2021-01-01) -
GRHL3 Promotes Tumor Growth and Metastasis via the MEK Pathway in Colorectal Cancer
by: Lin Tan, et al.
Published: (2021-01-01) -
Bilateral Multifocal Central Serous-Like Chorioretinopathy due to MEK Inhibition for Metastatic Cutaneous Melanoma
by: Scott D. Schoenberger, et al.
Published: (2013-01-01) -
Interdependence of coagulation with immunotherapy and BRAF/MEK inhibitor therapy: results from a prospective study
by: Malte Beckmann, et al.
Published: (2024-11-01)